PARP9 and metastatic prostate carcinoma: Although ARTD9 has been demonstrated to be catalytically inactive based on in vitro automodification studies [82], which is supported by structural considerations [6], it acts as an oncogenic factor in DLBCL [28] and possibly in metastatic prostate cancer cell lines [29].